miR-145-5p suppresses proliferation, metastasis and EMT of colorectal cancer by targeting CDCA3
miR-145-5p suppresses proliferation, metastasis and EMT of colorectal cancer by targeting CDCA3
复制标题
miR-145-5p通过靶向CDCA3抑制结直肠癌的增殖、转移和EMT
DOI：
10.1016/j.prp.2020.152872
复制
发表时间：
2020-04-01
影响因子：
2.8
通讯作者：
Wu, Jie
中科院分区：
文献类型：
--
作者：
Chen, Qing;Zhou, Lin;Wu, Jie
microrna在调节结直肠癌（CRC）的癌变过程中起着关键作用。尽管miR-145-5p在结直肠癌中的作用尚不清楚，但据报道，miR-145-5p在几种肿瘤中具有抗癌基因特性。我们的研究考察了miR-145-5p在结直肠癌中的功能及其潜在的潜在机制。从生物信息学和qRT-PCR分析中，miR-145-5p水平在CRC样本和细胞系中较低。分别用miR-145-5p模拟物和抑制剂处理LoVo和SW480细胞。细胞周期、CCK-8和EdU检测显示，过表达miR-145-5p可抑制细胞活力和Gl/S相转变。相反，miR-145-5p抑制剂促进细胞生长和细胞周期转变。miR-145-5p表达的升高也抑制了CRC细胞的迁移、侵袭和EMT，而miR-145-5p的降低则具有相反的作用。CDCA3被认为是miR-145-5p的下游效应物，与CRC中miR-145-5p的表达呈负相关。此外，将miR-145-5p抑制剂和si-CDCA3共转染SW480细胞，发现CDCA3可以逆转miR-145-5p的作用。综上所述，我们的研究结果表明miR145-5p可以通过靶向CDCA3在CRC中发挥抑瘤作用，并作为CRC的诊断和治疗生物标志物。
MicroRNAs play a critical role in regulating the carcinogenesis of colorectal cancer (CRC). Even though its role is unclear in CRC, miR-145-5p has been reported to have anti-oncogene properties in several tumors. Our research examined the function of miR-145-5p in CRC and the potential underlying mechanism. From the bioinformatics and qRT-PCR analysis, miR-145-5p levels were lower in CRC samples and cell lines. LoVo and SW480 cells were treated with miR-145-5p mimics and inhibitor, respectively. Cell cycle, CCK-8 and EdU assays revealed that overexpression of miR-145-5p suppressed cell viability and Gl/S phase transition. Conversely, miR-145-5p inhibitor promoted cell growth and cell cycle transition. Elevated miR-145-5p expression also suppressed the migration, invasion and EMT of CRC cells, while miR-145-5p reduction had a reverse effect. CDCA3 was identified as a downstream effector of miR-145-5p and had a negative correlation with the miR-145-5p expression in CRC. In addition, co-transfection of miR-145-5p inhibitor and si-CDCA3 showed that CDCA3 in SW480 cells could reverse the effect caused by miR-145-5p. In conclusion, our findings demonstrated that miR145-5p could act as a tumor suppressor in CRC by targeting CDCA3, and serve as a diagnostic and therapeutic biomarker of CRC.